Sentence examples for trial requirement from inspiring English sources

The trial requirement of real-name registration was announced last month.

The Qatari guideline contains the most protections at 19, followed by the Saudi "Clinical Trial Requirement Guidelines" with 15 protections.

As part of a clinical trial requirement, the microbiology laboratory at the HAS successfully participates in regular external quality assurance (EQA) programs addressing species identification and susceptibility testing.

Specifically, these efforts can be seen in the Qatari guidelines and the Saudi "Clinical Trial Requirement Guidelines" crafted by the SFDA, both of which contain the maximum number of protections 19 and 15 respectively.

This GCP structure is also used by the SFDA guidelines (I in Table  1), which are called the "Clinical Trial Requirement Guidelines" (2005), without mentioning GCP in its title.

Four of the journals did not have a specified policy about publishing pilot studies and mostly reported that pilot trials cannot be published if the standard is lower than a full clinical trial requirement.

They added that clinical trial requirements would make liquid nicotine commercially unviable, and are pressing for the European Union not to adopt new regulations.

All records were de-identified and only the range of each patient's age was documented, as per clinical trial requirements in The Netherlands.

In company news, Connectics plummeted 79%, after the drugmaker said that it would not seek FDA approval for relaxin, a treatment for the skin disease scleroderma, because it failed to meet Phase III trial requirements.

"Regulatory agencies like the FDA are contributing to the problem with a constant barrage of clinical trial requirements that make it harder, slower and more costly to develop antibiotics.” Another bad guy: "The National Institutes of Health was for many years [biased] against funding antibiotic research.”.

Since generic drugs are clinically identical versions of drugs already approved by the FDA, the FDA's clinical trial requirements before Hatch-Waxman did little more than deter generic manufacturers from selling their products in the United States, thus allowing name brands to maintain market monopolies years after their patent protections expired.